ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 09, 2022 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
January 13, 2022 07:00 ET
|
ONL Therapeutics
– Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – –...
ONL Therapeutics Names Connie Chang as Chief Operating Officer
January 19, 2021 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
December 22, 2020 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204
October 23, 2019 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Announces First-In-Human Clinical Study with ONL1204
October 08, 2019 07:00 ET
|
ONL Therapeutics
Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
August 22, 2019 11:54 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
August 22, 2019 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First in Human Clinical Trials
June 18, 2019 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases
May 17, 2017 08:05 ET
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - May 17, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...